Compare TRVG & RZLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TRVG | RZLT |
|---|---|---|
| Founded | 2005 | 2010 |
| Country | Germany | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 375.4M | 420.8M |
| IPO Year | 2015 | 2011 |
| Metric | TRVG | RZLT |
|---|---|---|
| Price | $4.90 | $4.72 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 6 |
| Target Price | $3.95 | ★ $9.67 |
| AVG Volume (30 Days) | 86.7K | ★ 1.1M |
| Earning Date | 05-05-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 26.32 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $15.59 | N/A |
| Revenue Next Year | $8.42 | N/A |
| P/E Ratio | $16.98 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.59 | $1.07 |
| 52 Week High | $5.91 | $11.46 |
| Indicator | TRVG | RZLT |
|---|---|---|
| Relative Strength Index (RSI) | 40.96 | 48.16 |
| Support Level | $2.76 | $4.51 |
| Resistance Level | $5.77 | $4.71 |
| Average True Range (ATR) | 0.31 | 0.26 |
| MACD | -0.08 | -0.02 |
| Stochastic Oscillator | 24.63 | 27.78 |
trivago NV is a hotel search company focused on reshaping the way travelers search for and compare hotels while enabling hotel advertisers to grow their businesses by providing access to a broad audience of travelers through the company's websites and apps. The platform allows travelers to make informed decisions by personalizing their hotel search and providing access to a deep supply of hotel information and prices. The company operates in three operating segments, namely the Americas, Developed Europe, and the Rest of the World. Its geographic areas are the United States, Germany, the United Kingdom, Canada, Japan, and all other countries.
Rezolute Inc is a clinical-stage biopharmaceutical company focused on developing therapies for rare and metabolic diseases. The company aims to address unmet medical needs in conditions like congenital hyperinsulinism, a rare endocrine disorder causing excessive insulin production and resulting hypoglycemia. Rezolute's pipeline includes drug candidates designed to improve patient outcomes while reducing treatment burdens. The company engages in research, development, and clinical trials to advance its therapies and collaborates with medical communities and patient groups to support its objectives. Revenue and value creation depend largely on successful product development and regulatory approvals.